Proteinuria affects some 100 million people worldwide and is a feature of kidney dysfunction of glomerular origin; it is also a risk factor for both renal and extrarenal diseases 1 . Podocytes and their foot processes, together with endothelial cells and the glomerular basement membrane (GBM), are key components of the ultrafiltration system in the glomerulus ( Supplementary Fig. 1a online) . Podocytes are attached to the GBM via a3b1 integrin 2,3 and a and b dystroglycan 4 . Podocyte foot processes are interconnected by the slit diaphragm, a modified adherens junction 5 . Proteinuric kidney diseases are typically associated with foot process effacement and/or slit diaphragm disruption driven by a rearrangement of the podocyte microfilament system 6 . Recent work has advanced our understanding of the molecular framework underlying podocyte structure, largely through the analysis of hereditary proteinuria syndromes and genetic models 7 . A few studies also suggest mechanisms for the far more common acquired proteinuric diseases 8, 9 . Despite this progress, there is a lack of cell-specific antiproteinuric therapeutics. An emerging concept in the regulation of podocyte function is the regulation of the podocyte cytoskeleton by proteases such as cathepsin L (refs. 8,10) . Cathepsin L induction in cultured podocytes is accompanied by an increase in cell motility 10 .
This increased motility of in vitro podocytes 10, 11 is best translated into foot process dynamics in vivo, in which podocytes remain locally attached to the GBM, whereas altered foot process dynamics lead to foot process effacement and proteinuria. In some forms of inflammatory glomerular diseases, such as crescentic glomerulonephritis, podocytes can move out of their microenvironment into areas of crescentic glomerular damage 12 . The concept of dynamic podocyte foot processes dates back to the 1970s, when studies showed that infusion of polycations can change foot process dynamics and cause their effacement 13 . Moreover, this event could be reversed by the infusion of polyanions 13 . Even though at present it is not possible to image foot process dynamics continuously in live animals, the results from the abovementioned studies suggest a highly dynamic podocyte foot process system. Moreover, electron-microscopic analysis commonly reveals small areas of foot process effacement in healthy kidneys possibly representing foot processes during a transitional stage 14 . Cancer cell motility is another situation in which cells can be hyperdynamic or participate in tissue invasion 15 . To explore potential molecular similarities between migrating cancer cells and motile podocytes during proteinuric conditions in vitro 10 , we decided to study molecules associated with cellular motility, such as the urokinase plasminogen activator receptor, uPAR (refs. 16,17) , in vivo during proteinuric disease.
uPAR is a glycosylphosphatidylinositol (GPI)-anchored protein that has been shown to be a proteinase receptor for urokinase but has also been involved in nonproteolytic pathways, mainly through its ability to form signaling complexes with other transmembrane proteins such as integrins, caveolin and G-protein-coupled receptors 17 . uPAR has important roles in wound healing, inflammation and stem cell mobilization, as well as in severe pathological conditions such as HIV-1 infection, tumor invasion and metastasis 18 . uPAR also exerts its function through interactions with proteins present in the extracellular matrix, including vitronectin 19, 20 .
Here, we analyzed the role of uPAR in podocytes during normal and disease conditions. We have analyzed mice deficient in Plaur (ref. 21) , Plau (ref. 22) , Vtn (ref. 23 ) and Itgb3 (ref. 24) , which encode uPAR, urokinase, vitronectin and b3 integrin respectively, and have challenged them with LPS, a treatment known to cause foot process effacement and proteinuria 9 . We show that uPAR is dispensable for normal renal filtration, yet it is required in podocytes, but not in endothelial cells, for loss of renal permselectivity. We also show that the signal originating from uPAR in podocytes is independent of its major ligand, urokinase, but is sufficient to cause proteinuria through its association with cell-matrix receptors. We propose a mechanism whereby uPAR activates avb3 integrin within lipid rafts 25 , causing proteinuria. Pharmacologically, this mechanism can be antagonized with small molecule integrin inhibitors or antibodies, leading to potent reduction of urinary protein loss. RESULTS uPAR induction in human and rodent proteinuric diseases uPAR protein is expressed in human glomerular cells (Fig. 1a) , including podocytes, which are identified by synaptopodin labeling 11 . We performed quantitative RT-PCR with glomeruli isolated from human kidney biopsies (Fig. 1b) 26 . We analyzed PLAUR expression in RNA samples from individuals without glomerular disease (n ¼ 8) and in individuals with focal segmental glomerulosclerosis (FSGS, n ¼ 14) and diabetic nephropathy (n ¼ 20), both conditions with podocyte foot process effacement and proteinuria 6 . We found lowlevel glomerular PLAUR mRNA expression in individuals without glomerular disease (Fig. 1b) . In contrast, individuals with biopsyproven FSGS had a significant increase in glomerular PLAUR expression (FSGS 0.35 ± 0.17 versus control 0.14 ± 0.02, *P o 0.05; Fig. 1b ). An even stronger induction of glomerular PLAUR mRNA expression (0.69 ± 0.21 versus control 0.14 ± 0.02, *P o 0.012) was found in people with diabetic nephropathy (Fig. 1b) .
To test which glomerular cells have increased uPAR expression, we examined the localization of uPAR within the kidney in three different animal models of proteinuria and podocyte foot process effacement, including the puromycin aminonucleoside nephrosis (PAN) model 27 , the LPS model of transient proteinuria 9 and the NZB/W F1 model of systemic lupus erythematosus 28 . We found low expression of uPAR in glomeruli from control rats or mice (Fig. 1c) localized in podocytes, as indicated by colabeling with synaptopodin, a marker of this cell type 29 . In contrast with the control results, expression of uPAR protein in all proteinuria models was substantially increased in glomerular cells, including podocytes (Fig. 1c) . Of note, in NZB/W F1 lupus mice, uPAR was preferentially found in crescentic areas of the glomerulus (Fig. 1c) . Such a distribution has been reported in murine glomerulonephritis, in which podocytes can populate cellular crescents 12 . We also found expression of uPAR in proximal tubular cells that appeared unchanged under normal and disease conditions (data not shown). We next used cultured differentiated podocytes, which express all known podocyte proteins including nephrin and podocin 30 ( Supplementary Fig. 1b) , to study the expression and localization of uPAR. Increased uPAR protein expression was observed in LPS-and PAN-treated cells ( Supplementary Fig. 1c ) in which uPAR was preferentially located at the podocyte cell membrane ( Supplementary Fig. 1d ). Analysis of the uPAR ligand vitronectin revealed prominent staining of vitronectin in human kidney podocytes ( Supplementary Fig. 2a online) . We detected an increase in vitronectin labeling in the podocytes of PAN rats, LPS and lupus mice when compared to controls ( Supplementary  Fig. 2b ). Overall, the vitronectin expression profiles in podocytes were similar to the pattern we have observed for uPAR.
To define the subcellular localization of uPAR within glomerular cells, including within podocytes, we analyzed uPAR localization in normal and diabetic rats (Fig. 1d) , as PLAUR mRNA induction is strongest during diabetic nephropathy in humans (Fig. 1b) . We performed semiquantitative immunogold analysis of uPAR in glomerular walls of normal and 3-and 12-month-old diabetic rats 31 . Under normal conditions, uPAR expression was observed in all cell types of the glomerulus (Table 1) , including podocytes (Fig. 1d) . The morphometric analysis revealed a homogeneous distribution of uPAR in podocytes, mesangial and endothelial cells ( Table 1) . Twelve-month-old diabetic rats showed increased uPAR labeling in all cells of the glomerular tuft (Fig. 1d) . Notably, podocyte uPAR expression was increased in 3-and 12-monthold diabetic rats, but only in basal membrane aspects of the foot processes. uPAR in podocytes is required for effacement and proteinuria To explore whether uPAR has a direct role in regulating podocyte foot process structure and function, we next compared the foot process morphology of wild-type and Plaur À/À mice before and after administration of LPS. Morphologically, there was no difference between wild-type and Plaur À/À mice in podocyte foot process structure (Fig. 2a) . However, after LPS injection, we found podocyte foot process effacement in wild-type but not Plaur À/À mice (Fig. 2a) , suggesting a functional link between the development of podocyte foot process effacement and uPAR expression. To test whether the protection from LPS-induced foot process effacement in Plaur À/À mice could be overcome by restoring glomerular uPAR expression, we used our previously reported gene delivery protocol to deliver Plaur cDNA 8, 32 . Twenty-four hours after gene delivery of a plasmid encoding uPAR, we found uPAR expression in glomerular cells, including podocytes, of Plaur À/À mice (Fig. 2b) . To monitor expression of uPAR after gene delivery, we performed immunoblotting. Fourteen hours after Plaur delivery, we found uPAR protein in the liver and, at lower expression levels, in glomeruli (Fig. 2c) . The restoration of uPAR expression did not change the morphology of podocyte foot processes (Fig. 2d) , suggesting that exogenous uPAR behaves similarly to endogenous uPAR. However, concomitant administration of LPS and Plaur cDNA to Plaur À/À mice resulted in foot process effacement (Fig. 2d) , similarly to the results in LPStreated wild-type mice expressing endogenous uPAR (Fig. 2a) . In contrast, we did not find any foot process changes in Plaur À/À mice that had received vector control, even after coadministration of LPS (Fig. 2d) .
To study the functional consequences of uPAR reconstitution, we analyzed the urinary protein excretion of wild-type, Plaur À/À and uPAR-reconstituted Plaur À/À mice before and after LPS injection. Whereas PBS-treated control mice and Plaur À/À mice did not have any significant proteinuria, the injection of LPS induced significant proteinuria in wild-type but not Plaur À/À mice and Plaur À/À mice that had received control plasmids (Fig. 2e) . These data indicate that Plaur À/À mice are protected from urinary protein loss. Most notably, Plaur À/À mice reconstituted with Plaur cDNA developed heavy proteinuria but, like wild-type mice, only after LPS injection ( Fig. 2e) . The degree of proteinuria was comparable in LPS-treated wild-type and Plaur cDNA-reconstituted Plaur À/À mice. In summary, these data strongly suggest that uPAR is required for the development of LPS-induced proteinuria in mice.
To test whether uPAR exerts its effects on proteinuria development solely by altering podocyte function or whether it also alters glomerular endothelial cell function, we carried out gene transfer of Plaur cDNA under the control of two different promoters allowing cellspecific expression of uPAR in podocytes (NPHS2-Plaur) 33 or endothelial cells (ICAM2-Plaur) 34 . Cell type-specific expression of uPAR was monitored by double immunofluorescence labeling of uPAR and synaptopodin (Fig. 2f) or the endothelial marker CD31 (ref. 35 ; Fig. 2g ). Whereas the expression of uPAR in podocytes was required for LPS-induced proteinuria, the expression of uPAR in endothelial cells was associated with LPS resistance (Fig. 2h) . These results show that podocyte but not endothelial uPAR is required and sufficient for LPS-induced proteinuria.
uPAR orchestrates podocyte motility To better understand uPAR function in podocytes, we considered uPAR's role in cell motility 17 . Podocyte foot process effacement may represent a motile event, resulting in spreading of podocyte foot processes on the GBM. Thus, we studied podocyte motility before and after stable knockdown of Plaur with siRNA ( Supplementary  Fig. 3a,b online) . We then used a modified multiwell Boyden chamber assay to assess the random migration of differentiated podocytes on type 1 collagen (data not shown) and vitronectin, a known binding partner of uPAR (refs. 19,20) that is induced in proteinuric glomeruli ( Supplementary Fig. 2b ). LPS or PAN treatment for 24 h significantly promoted the migration of wildtype podocytes (Fig. 3a,b) . In contrast, the knockdown of Plaur significantly decreased the number of migrating podocytes under normal conditions and after treatment with LPS or PAN (Fig. 3a,b) . These results show that podocyte motility is increased in response to LPS or PAN in a uPAR-dependent manner.
We also analyzed the effect of uPAR on the spatial motility of podocytes with a modified scrape-wound assay 11 . Compared to control cells, LPS or PAN treatment significantly promoted podocyte wound closure after 24 h (Fig. 3c,d ), a finding that we also obtained in a similar pattern at time points 12, 24 and 48 h ( Supplementary  Fig. 3c ). The addition of external urokinase did not alter podocyte directional migration ( Supplementary Fig. 3d ), but knockdown of Plaur strongly reduced podocyte-directed motility before and after administration of LPS or PAN (Fig. 3c,d and Supplementary Fig. 3c) . Together, these data show that uPAR is important for podocyte motility.
uPAR activates avb3 integrin in podocytes Because uPAR is a GPI-anchored protein without a cytoplasmic tail, it is generally believed that signal transduction from uPAR involves lateral interactions with membrane proteins such as integrins 17 . Most recently, one study showed that uPAR-induced cell adhesion and migration requires vitronectin binding, which can occur independently of uPAR interactions with integrins 20 . Podocyte motility on vitronectin is enhanced in a uPAR-dependent fashion (Fig. 3a-d) , and vitronectin is induced in glomeruli during proteinuria (Supplementary Fig. 2b ). Thus, it appeared possible that a uPAR-vitronectin complex or an uPAR-vitronectin-integrin complex facilitates podocyte motility and promotes foot process effacement in response to LPS. Integrins can be in an inactive or active conformation (ref. 36 ; Fig. 3e ). The latter conformation is stimulated by integrin association with interacting agonists, such as domain 3 of uPAR, which is important for a5b1 integrin interaction 37, 38 . An integrin-interacting sequence in domain 2 of uPAR, which acts as a chemotactic epitope activating avb3-dependent signaling pathways, has recently been identified 39 . Given our findings of uPAR and vitronectin expression in the glomerulus, we were particularly interested in the vitronectin receptor avb3 integrin 36 . Indeed, the localization of avb3 integrin 32 and the distribution of uPAR (Fig. 3f) in podocyte foot processes were similar. In addition, uPAR interacts with b3 integrin ( Supplementary  Fig. 4a online) . Thus, we hypothesized that avb3 integrin may provide a functional link between uPAR, podocyte migration and development of proteinuria. Mice lacking b3 integrin or the avb3 integrin ligand vitronectin are protected from LPS-induced proteinuria (Fig. 3g) . This means that both vitronectin and b3 integrin are required for LPS-induced proteinuria, but either one is dispensable for normal renal development and function (Fig. 3g and data not shown) . Given the extent of the published uPAR interactome and the importance of a3b1 integrin in podocyte development 3 , we also analyzed the potential contribution of a3b1 integrin to the uPAR signaling cascade in podocytes by using a cDNA for PLAUR that encodes the uPAR mutant D262A, which is unable to bind a3b1 integrin in humans 38 and in mice ( Supplementary Fig. 4b ). The expression of uPAR D262A in podocytes led to the development of LPS-induced proteinuria (Fig. 3g) , supporting the idea that uPAR in podocytes preferentially signals through avb3 integrin. Because uPAR is involved in pathways both dependent on and independent of urokinase 17 , we also explored the contribution of urokinase to uPAR-dependent proteinuria pathways by treating Plau À/À mice with LPS. Notably, these mice developed proteinuria, suggesting that urokinase is not required for the LPS-mediated effects of uPAR on the kidney filtration barrier (Fig. 3g) .
Plaur À/À , Itgb3 À/À and Vtn À/À mice have no overt renal phenotypes under normal conditions (Figs. 2e and 3g) , suggesting that uPAR signaling in podocytes is not required for normal glomerular filtration. However, all of these molecules are required for the development of urinary protein loss. In light of these findings, we reasoned that changes in the activation of avb3 integrin under disease conditions may cause increased podocyte motility and foot process effacement after administration of LPS. To explore this idea, we studied the expression of total and active b3 integrin in kidney sections from wild-type and Plaur À/À mice. We visualized total podocyte b3 integrin expression in wild-type and Plaur À/À mice before and after injection of LPS (Fig. 4a) . The expression of b3 integrin in podocytes was unchanged in wild-type and Plaur À/À mice both before and after LPS administration (Fig. 4a) . We next looked for the presence of active b3 integrin in podocytes, for which we used AP5 antibody. This antibody recognizes an N-terminal epitope of b3 integrin that is only accessible when the integrin is in its active conformation 40 . To evaluate whether AP5 could be used to detect active b3 integrin in podocytes, we first tested the effect of divalent cations on the binding pattern of AP5 to b3 integrin by flow cytometry of normal (data not shown) and LPStreated cultured podocytes 41 (Fig. 4b) . We found a calcium-dependent binding pattern of AP5 to b3 integrin similar to that previously reported in other cell types 41 . Active b3 integrin abundance was low in wild-type (Fig. 4c, WT) and Plaur À/À mice (Fig. 4c , Plaur À/À ) under normal conditions. This finding suggests that avb3 integrin has a low basal activity even in the absence of uPAR. LPS treatment of wild-type mice was associated with a strong induction of podocyte AP5 labeling (Fig. 4c) . This induction was absent in LPS-treated Plaur À/À mice (Fig. 4c , Plaur À/À + LPS). We also observed colocalization of AP5 labeling at sites of uPAR overexpression in cultured podocytes, but not in podocytes in which Plaur was downregulated by siRNA treatment (Fig. 4d) , suggesting that uPAR is required for the activation of b3 integrin in podocytes.
As an additional readout for active b3 integrin expression, we analyzed the activity of the small GTPases Cdc42 and Rac1 in glomerular lysates from wild-type and Plaur À/À mice before and after administration of LPS (Fig. 4e) 42 . The activity of Rac1 was increased in LPS-treated wild-type but not Plaur À/À mice (Fig. 4e,  top) . We observed a similar induction pattern for Cdc42 activity (Fig. 4e, bottom) . In some experiments, we co-injected wild-type mice with LPS and cyclo-[Arg-Gly-Asp-D-Phe-Val]-RGDfV (cycloRGDfV), known from clinical cancer trials as Cilengitide), which is used as a specific inhibitor of avb3 integrin 43 . This treatment inhibited the induction of active Rac1 and Cdc42 in the glomeruli of LPS-treated mice (Fig. 4e) . These findings support the concept that uPAR is required for the activation of podocyte avb3 integrin after LPS treatment.
We next looked for subcellular compartments in which uPAR and b3 integrin can associate with each other. Studies suggest that many regions of the podocyte foot process membrane and slit diaphragm are rich in cholesterol, and several slit diaphragm proteins, such as podocin and nephrin, are associated with lipid rafts 44 . Plasma membrane lipid rafts help to compartmentalize signal transduction events within different membrane regions 25 , and uPAR, as a GPI-anchored protein, is known to be found in lipid-rich membrane compartments 17 . We wondered whether uPAR and b3 integrin associate together within lipid rafts in podocytes, and thus we performed sucrose density gradient assays of whole cellular extracts from cultured podocytes before and after LPS treatment (Fig. 5a) . We found that uPAR and b3 integrin are mainly associated with nonraft fractions in control podocytes. However, after LPS treatment, both uPAR and b3 integrin were enriched within the lipid raft fraction (Fig. 5a) . The functional association of uPAR and b3 integrin within lipid rafts was fostered by the observation that disruption of lipid rafts by methylb-cyclodextrin treatment 45 abrogated the activation of b3 integrin in response to LPS (Fig. 5b) . These data suggest that b3 integrin can be activated by uPAR within lipid-rich domains of the podocyte plasma membrane.
Interference with avb3 integrin modifies proteinuria If the activation of avb3 integrin is a key signal that mediates uPARinduced cellular events leading to proteinuria, expression of a constitutively active b3 integrin should be sufficient to induce proteinuria, even in the absence of uPAR. Therefore, we used an ITGB3 cDNA that encodes a protein lacking amino acids 616-690 of the C-terminal region of the b3 ectodomain (ITGB D616-690 ). This mutation confers constitutive activity to the b3 protein 46 . We performed gene transfer of this active ITGB3 construct into Plaur À/À mice and monitored the activity of b3 integrin in podocytes by immunofluorescent doublelabeling of synaptopodin and b3 integrin. We labeled b3 integrin with WOW-1 antibody, which is known to recognize constitutively active b3 protein 47 . Plaur À/À mice positive for WOW-1 labeling in podocytes developed proteinuria (Fig. 5c) , whereas littermates that received normal ITGB3 or vector control had very low podocyte WOW-1 labeling and no proteinuric response (Fig. 5c) . We also performed experiments in Itgb3 À/À mice, but instead of using ITGB3 D616-690 , we administered ITGB D723R , which confers constitutive activity as well 48 . The expression of this active b3 integrin mutant was detected by positive WOW-1 labeling in the podocyte and by the induction of heavy proteinuria in Itgb3 À/À mice (Fig. 5d) . In contrast with these results, the expression of Plaur cDNA (data not shown) or of wild-type ITGB3 (Fig. 5d) in Itgb3 À/À mice did not result in WOW-1 labeling or urinary protein loss. These data corroborate our findings that activation of b3 integrin is sufficient to cause proteinuria. We also performed experiments with an antibody that inhibits b3 integrin function. Wild-type mice that were co-injected with LPS and a monoclonal antibody to b3 integrin did not develop proteinuria in response to LPS (Fig. 5e) . This blocking antibody was also able to reduce podocyte motility significantly during LPS treatment in vitro (Fig. 5f) , connecting increased podocyte motility in vitro to the development of proteinuria in vivo.
Finally, we used different concentrations of cyclo-RGDfV to specifically block active avb3 integrin. Cyclo-RGDfV was injected into LPS-treated wild-type mice (Fig. 5g) . Whereas the administration of cyclo-RGDfV to normal mice had no effect, mice that received both LPS and cyclo-RGDfV showed an attenuated course of proteinuria in a cyclo-RGDfV dose-dependent manner compared to control mice that had received only LPS (Fig. 5g) . We also performed a treatment study in which wild-type mice were injected twice with LPS to induce and maintain high levels of proteinuria before some mice received cyclo-RGDfV and control animals received PBS (Fig. 5h) . We observed a substantial reduction of proteinuria in cyclo-RGDfV-treated mice 18 h after administration of this compound. Proteinuric mice that had received PBS instead did not show any resolution of urinary protein loss during this time (Fig. 5h) .
These data show that increased activity of avb3 integrin is important for proteinuria development and demonstrates the feasibility of treating proteinuria by pharmacologically interfering with avb3 integrin in podocytes.
DISCUSSION
Proteinuria is a predictor of poorer outcome and faster progression of renal insufficiency 1 . In an attempt to slow down progression of renal disease, the mainstay of therapy is blockade of the renin-angiotensin system 49 . Other treatments, including immunomodulators such as steroids, cyclosporine and alkylating agents, depend on the clinical and histopathological diagnosis. Therapeutic intervention for proteinuric kidney diseases is hampered by at least two key points: interventions are only aimed to slow down the progression of glomerular disease, and cell-specific therapies for proteinuria syndromes are presently not available. Here we describe a mechanism in podocytes that can be targeted pharmacologically. We found an induction of uPAR expression in podocytes during proteinuric kidney diseases (Fig. 1b) . uPAR is required for podocyte migration and LPS-induced foot process effacement and proteinuria in mice through a mechanism that includes lipid-dependent activation of avb3 integrin. Collectively, our findings define a new signaling pathway in podocytes that involves uPAR, avb3 integrin and vitronectin. uPAR is expressed in all glomerular cells, yet it is not required for normal renal function, as the Plaur À/À mice have a normal renal phenotype. Of note, uPAR is required for the development of podocyte foot process effacement and proteinuria, which suggests that uPAR-inducible pathways are required for the remodeling of the filtration barrier. uPAR's importance in the development of proteinuria stems from its action in podocytes, which we showed by using cell-specific promoter elements. Nonetheless, the role of uPAR in the other glomerular cell types, as well as the potential interactions podocyte uPAR may have with other integrins and nonintegrins, needs to be studied further.
We recently described LPS resistance in mice lacking cathepsin L (ref. 8) and B7-1 (ref. 9) similar to our data with mice lacking uPAR. Notably, there is data linking Ras signaling with the urokinase system and with cathepsin L in cancer cells 50 , and B7-1 in podocytes is stimulated by LPS, as are cathepsin L (ref. 8) and uPAR. It will be necessary to see how all these pathways cooperate. The functional value of active avb3 integrin as a downstream effector for increased podocyte motility, which in this case equals foot process effacement and proteinuria, is an attractive outlook for integrin or uPAR inhibitor studies in humans. Because blockade of uPAR and avb3 integrin are possible interventions that are currently being studied in clinical cancer trials (such as the trial of Cilengitide in glioblastoma patients), these approaches may prove to have additional benefits as cell-specific treatments of urinary protein loss.
METHODS
Antibodies. Antibodies used in this study are listed with their sources as follows: AP5 antibody to active b3 integrin, Genetic Testing Institute; antibody to WOW-1 fragment (Fab) 47 was a gift (see Acknowledgments); monoclonal antibody to CD61, BD Pharmingen; antibodies to CD31 (ER-MP12), vitronectin (H-270) and uPAR (FL-290), Santa Cruz Biotechnology; polyclonal antibody to uPAR-1, R&D Systems; monoclonal antibody to a-tubulin, Calbiochem; polyclonal antibody to b3 integrin, Chemicon; polyclonal antibody to caveolin-1 and monoclonal antibodies to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Flag epitope, hemagglutinin and the transferrin receptor, Sigma; mouse monoclonal antibody to synaptopodin (G1), rabbit polyclonal antibody to synaptopodin (NT; ref. 29) and rabbit polyclonal antibody to podocin (ref. 44) were described before; rabbit polyclonal antibody to nephrin was also a gift (see Acknowledgments).
Animals and treatments. All animal studies were approved by the Subcommittee on Research Animal Care of the Massachusetts General Hospital, protocol number 2004N000289/2. All mice were on either a C57BL/6 background or a mixed background of 75% C57BL/6 and 25% 129 Swiss. Plaur À/À mice 21 , Plau À/À mice 22 , Vtn À/À mice 23 and Itgb3 À/À mice 24 were described before. We used the LPS mouse and rat PAN models as previously reported 9, 27 . NZB/W F1 mice were purchased from the Jackson Laboratory at 19 weeks of age and analyzed after 20 weeks, when proteinuria and lupus glomerulonephritis were present. For the diabetic nephropathy rat model, we used Sprague-Dawley rats treated with streptozotocin 30 .
Human subjects. Human renal biopsies were obtained with informed consent and were collected in a multicenter study (the European Renal cDNA Bank) according to the guidelines of the European Renal cDNA Bank Consortium. We analyzed microdissected glomeruli from 34 individuals with proteinuric diseases (FSGS; n ¼ 14; diabetic nephropathy, n ¼ 20) and 8 control subjects. Control tissue was derived from pretransplantation kidney biopsies during cold ischemia time from seven living and one cadaveric donor (n ¼ 8).
Quantitative real-time PCR. We performed TaqMan real-time RT-PCR as previously described 26 .
Immunocytochemistry. We stained human glomerular biopsies with uPAR-, vitronectin-or synaptopodin-specific antibodies following standard protocols 8 . We immunolabeled cultured podocytes as previously described 8, 9 .
Transmission electron microscopy, immunoelectron microscopy and morphometry. We performed transmission electron microscopy and immunoelectron microscopy according to the standard protocols 8, 9 . We recorded micrographs of immunolabeled renal glomeruli (420 micrographs per animal and time point) and evaluated them using morphometrical techniques 51 .
GTPase activity assay. We measured GTPase activity in glomerular lysates with a Rho/Rac/Cdc42 activation assay kit (Cell Biolabs) following the manufacturer's protocol. We isolated glomeruli from wild-type and Plaur À/À mice, some of them treated with LPS (t ¼ 0), with cyclo-RGDfV every 8 h for 24 h, or both, by a standard sieve technique 8 .
In vivo gene delivery. We performed gene delivery with the TransIT in vivo gene delivery system (Mirus) as described previously 8 Flow cytometry. We exposed differentiated podocytes to LPS before we incubated them with the following calcium solutions in the presence of 5 mg/ml AP5 for 1 h: 1 mM EDTA, PBS without Ca 2+ or Mg 2+ , 0.1 mM CaCl 2 , 0.4 mM CaCl 2 , 1 mM CaCl 2 and 2 mM CaCl 2 .
Cell culture and transient transfection. We transfected HEK293 cells and podocytes as reported previously 11 .
Western blotting and co-immunoprecipitation. We performed immunoblotting and co-immunoprecipitation experiments as described 11 .
Migration assay. We analyzed podocyte migration in a 12-well chemotaxis chamber (Neuro Probe) according to the manufacturer's protocol. We studied the directional movement of podocytes with a wound healing assay 11 .
Sucrose gradient ultracentrifugation. We performed sucrose gradient ultracentrifugation as described 45 .
Blockade of avb3 integrin in mice. We injected cyclo-RGDfV (Biomol) at 1, 5 and 20 mg per kg body weight intravenously into mice three times at 8-h intervals. Control mice received an equal amount of PBS instead or a control peptide, cyclo-RAD (Biomol; data not shown). Immediately after the first injection, we injected 200 mg of LPS intraperitoneally into each mouse to induce proteinuria. We collected urine for a Bradford assay 24 h after LPS injection 8 .
For cyclo-RGDfV treatment, we injected C57BL/6 mice twice with LPS (at 0 and 24 h) to induce and maintain proteinuria. Forty-eight hours after the first injection, we administered cyclo-RGDfV (n ¼ 6) intravenously (25 mg/kg body weight in 0.5 ml of PBS). Controls (n ¼ 5) received the same volume of PBS alone. We collected urine at 0, 48 and 66 h for urine protein analysis.
For blockade of b3 integrin with antibody to CD61, we injected wild-type mice with PBS alone (control), LPS and CD61 monoclonal antibody or LPS and IgG isotype control antibody. We administered the antibody intravenously 4 h after LPS injection to a final concentration of 10 mg/ml. We collected urine at time points 0, 4 and 24 h for protein analysis.
Statistical analysis. We performed statistical analyses by the Student's paired or non-paired t-test or Mann-Whitney U-test. We rejected the null hypothesis at P value 0.05. Values are presented as mean ± s.d. unless stated otherwise.
Note: Supplementary information is available on the Nature Medicine website.
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